Several specific inhibitors of EZH2, which catalyzes tri-methylation of histone H3 at Lys 27 (H3K27me3), have been developed, and Tazemetostat has been approved by the FDA for epithelioid sarcoma [31], diffuse large B-cell lymphoma and relapsed or refractory follicular lymphoma [32]. Here, EZH2 is linked to diffuse large B-cell lymphoma.